Breaking News, Trials & Filings

Eisai, Biogen’s Lecanemab Gets Breakthrough Designation in AD

Based on pre-specified analysis showing consistent reduction of clinical decline across several clinical and biomarker endpoints at the highest doses.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Eisai Co., Ltd. and Biogen’s lecanemab (BAN2401), an investigational anti-amyloid beta (Abeta) protofibril antibody for the treatment of Alzheimer’s disease (AD), was granted Breakthrough Therapy designation from the FDA.   Breakthrough Therapy designation is an FDA program intended to expedite the development and review of medicines for serious or life-threatening conditions. The benefits of a Breakthrough Therapy designation includes more guidance on the development program and eligibi...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters